CTOs on the Move

ZERO - The End of Prostate Cancer

www.zerocancer.org

 
ZERO - The End of Prostate Cancer is a 501 non-profit organization dedicated to prostate cancer education, testing, patient support, research and advocacy.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

SoftScript

SoftScript is a Santa Monica, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Amrus Enterprises

Amrus Enterprises is a Fords, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Accucare Inc

Accucare Inc is a Asheville, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Versartis

Versartis, Inc. (NASDAQ: VSAR) is an endocrine-focused biopharmaceutical company developing novel, long-acting medicines to transform treatment for patients with endocrine disorders. The company is led by a management team with rich experience and expertise discovering, developing and commercializing innovative therapeutics for the life sciences industry. Versartis` mission is to develop, manufacture and commercialize novel therapeutics to improve and transform treatment for patients with orphan endocrine disorders. Versartis is well-positioned to deliver a major innovation to the global growth hormone deficiency (GHD) market with the company`s most advanced clinical candidate, somavaratan. Somavaratan is a novel, long-acting form of recombinant human growth hormone that is in global late-stage clinical trials to treat GHD in children and adults. Twice-monthly somavaratan is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving compliance/adherence and treatment outcomes.

Biological Dynamics

Biological Dynamics Inc. is an early stage company that has developed a proprietary AC Electrokinetic technology to rapidly extract nanoparticles in high-conductance physiological solutions. Biological Dynamics was founded in 2008 by Raj Krishnan and David Charlot, Bioengineering PHD graduates from the University of California, San Diego (UCSD). Our vision is to enable healthcare practitioners to detect, diagnose and monitor cancer and other diseases from a simple blood draw (or other bodily fluid) and rapidly intervene, increasing patient survivability while driving down the total burden costs.